Antigenic variation in gp120s from molecular clones of HIV-1 LAI.
暂无分享,去创建一个
J. Sodroski | J. Moore | H. Yoshiyama | D. Ho | J. Robinson
[1] M. Robert-Guroff,et al. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.
[2] J. Sodroski,et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. , 1985, Science.
[3] Robin A. Weiss,et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.
[4] M. Gonda,et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. , 1985, Science.
[5] Olivier Danos,et al. Nucleotide sequence of the AIDS virus, LAV , 1985, Cell.
[6] Mark L. Pearson,et al. Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.
[7] E. Reddy,et al. HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients , 1985, Cell.
[8] Robin A. Weiss,et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.
[9] Hans Wolf,et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.
[10] A. Dalgleish,et al. Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.
[11] H. Gendelman,et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.
[12] V. Tkachuk,et al. Morphological alterations in endothelial cells from human aorta and umbilical vein induced by forskolin and phorbol 12-myristate 13-acetate: a synergistic action of adenylate cyclase and protein kinase C activators. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[13] A J Langlois,et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. , 1986, Science.
[14] L. Arthur,et al. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[15] J K Nicholson,et al. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.
[16] L. Jagodzinski,et al. Complete nucleotide sequences of functional clones of the AIDS virus. , 1987, AIDS research and human retroviruses.
[17] G. Shaw,et al. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions , 1987, Journal of virology.
[18] R. Weiss,et al. Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.
[19] J. Goudsmit. Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. , 1988, AIDS (London).
[20] H. Lyerly,et al. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. , 1988, AIDS research and human retroviruses.
[21] S. Matsushita,et al. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope , 1988, Journal of virology.
[22] J. Cohen,et al. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120. , 1989, Journal of immunology.
[23] T. H. Lee,et al. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.
[24] Linear versus conformational variation of V3 neutralization domains of HIV‐1 during experimental and natural infection , 1989, AIDS.
[25] J. Moore,et al. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. , 1989, AIDS.
[26] A J Langlois,et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Profy,et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.
[28] M. Reitz,et al. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.
[29] J. Davide,et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.
[30] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[31] J. Moore,et al. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. , 1990, AIDS.
[32] R. Gallo,et al. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees , 1990, Journal of virology.
[33] J. Moore,et al. Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. , 1990, AIDS research and human retroviruses.
[34] M. Champe,et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.
[35] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[36] N. Haigwood,et al. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Moore,et al. The role of the V3 loop of gp120 in HIV infection. , 1991, AIDS.
[38] D. Ho,et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[39] D. Ho,et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.
[40] K. Steimer,et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.
[41] J. Goudsmit,et al. Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] J. Sodroski,et al. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.
[43] R. Cheynier,et al. LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.
[44] G. Pauli,et al. Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120. , 1992, The Journal of general virology.
[45] J. Sodroski,et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.
[46] K. Steimer,et al. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons , 1992, Journal of virology.
[47] D. Ho,et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.
[48] W. Morrow,et al. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. , 1992, Journal of immunology.
[49] J. Sodroski,et al. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.
[50] G. Nakamura,et al. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1 , 1993, Journal of virology.
[51] G K Lewis,et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.
[52] J. Sodroski,et al. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.
[53] J. Hansen,et al. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. , 1993, The Journal of general virology.
[54] Q. Sattentau,et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.
[55] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[56] P. Westervelt,et al. Structure—function relationships of the HIV‐1 envelope V3 loop tropism determinant: evidence for two distinct conformations , 1993, AIDS.
[57] J. Moore,et al. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.